Rangering i aksjer
#30386
Aelis Farma S.A., a French biotechnology company founded in 2013 and... Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
Aksjekurs
$1.25
Sist synkronisert: 2026-08-18
Handel Aelis Farma S.A. (AELIS)
Pris AELIS pris med markedsverdi på B
Markedsverdi av Aelis Farma S.A.(AELIS)
Markedsverdi: $17.05M
Per August 2026 har Aelis Farma S.A. en markedsverdi på $17.05M. Dette gjør Aelis Farma S.A. til det 30386th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Aelis Farma S.A. fra 2022 til 2026
AELIS sammenlignet med topp 5 mest populære stocks
| Pris på AELIS |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.307T
|
+31,129,810.13%
|
|
|
|
|
$4.551T
|
+26,695,786.97%
|
|
|
|
|
$4.154T
|
+24,370,577.33%
|
|
|
|
|
$3.589T
|
+21,051,335.33%
|
|
|
|
|
$2.797T
|
+16,406,999.17%
|
